Australia: Do gene patents pose problems for progress to more advanced sequencing techniques?

HG Intellectual Property Alert: 9 September 2014
Last Updated: 11 September 2014
Article by Hayden Delaney and Hayley Tarr

This past week in Cancer Voices Australia v Myriad Genetics, the full bench of the Federal Court upheld the decision that human genes are patentable.

In this Alert, Partner Hayden Delaney and Associate Hayley Tarr explore the possible consequences of this recent Myriad Genetics decision for genome sequencing innovation.

Key points:

  • Given the pace of technological advancement in the field of genetics, it is insufficient to evaluate the legal developments as against what is currently possible. Rather, we must think a step ahead to what will soon be feasible.
  • When factoring in what will soon be feasible, the patenting of human genes may impede development and use of new gene sequencing technologies.
  • This may interfere with medical research more than even Cancer Voices Australia have anticipated.

Patenting of human genes

To be patentable, an invention must comprise an artificially created state of affairs. The full bench of the Federal Court held that isolated genes do not exist in nature and are therefore an artificially created state of affairs. In this way, even though a gene is patentable, you do not infringe the patent simply by existing. Nor do you infringe the patent each time your cells reproduce and therefore create a new copy of that gene. This is because, all of this occurs while the gene is part of the genome. The monopoly granted by the patent only exists where the gene is separated from the genome.

For organisations such as Cancer Voices, even this narrowed scope of monopoly is hugely objectionable. The primary use for genes which have been separated from the genome is for medical research. Thus Cancer Voices and other critics of the Myriad Genetics decision argue that patents over human genes increase the cost of medical research using those genes. This, in turn, delays the discovery of new treatments or renders them inaccessible (due to affordability issues).

Yet, others are less concerned, citing reasons why the impact will be minimal. They claim that important genetic research techniques will remain unaffected.

Gene sequencing - how it's done

One such important research technique that is currently popularly thought will remain unaffected is genetic sequencing, such as is done by organisations such as Queensland's Diamantina Institute. Genetic sequencing is a method of sequencing a person's entire genome, to diagnose disease or identify any predispositions for a disease. Genetic sequencing is now both affordable and readily available, and is set to become a standard component of all medical treatments in the very near future. This is the new age of medicine.

Genome sequencing will almost certainly revolutionise medical treatment. Once a person has had their genome sequenced, doctors will be able to tailor their medical treatments in light of their genome. Given that the majority of adverse drug reactions arise in persons with unexpected gene variations and that the difference between success or failure of a medicine in targeting a particular cancer boils down to the specific genetic mutation causing that cancer, this targeting process will have profound effects in terms of whether many patients either live or die.

In layman's terms, the current technique for sequencing a genome is to cut the genome up into millions of tiny pieces and then have a computer reassemble those pieces like a puzzle. In putting those pieces of the puzzle together and seeing where they fit, the computer realises the sequence of the genome. There are problems with this technique however, and scientists will be looking to improve upon it.

Currently, most whole genome or whole exome sequencing is conducted by first splicing the DNA sequence into such small fragments that no single fragment comprises an entire gene. Thus, no genes are isolated from the genome, meaning that human gene patents are not infringed.

Once the small fragments have been created, computers are then enlisted to recreate the genome by aligning the small fragments (by matching the overlapping nucleotide sequences that exist on the ends of each of the small fragments). This has inherent problems associated with parts of the sequence that repeat. Computers cannot tell where the genetic material has been spliced and errors occur in the recreation process.

Genetic sequencing - how it could soon be done

One way of rectifying this would be to move to splicing the gene at the start of the actual gene locus, by splicing at a promoter region for example. Obviously, if we knew how to do this, we would be doing it already. It would simplify the gene sequencing process dramatically.

Researchers are no doubt brainstorming and experimenting with methods to achieve this desired outcome. Given the rate of advancement in genome sequencing methods to date, with the cost of sequencing of a human genome dropping from $3 billion dollars to $1000 in the last decade alone, it would not be surprising if the efforts of these brilliant researchers results in technologies such as this sooner than we might expect.

Achievement of this desired outcome would unfortunately cause new problems to arise because complete genes would then be isolated from the genome during the gene sequencing process, resulting in infringement of human gene patents.


Therefore, granted, it is true that whole genome sequencing and whole exome sequencing does not currently result in infringement of human gene patents because our existing sequencing techniques require that we splice the DNA into such small fragments that no full gene is isolated. Nevertheless, just because this is the current state of affairs does not obviate the need for any further thought on the matter. We should heed that science is changing. Methods of sequencing are changing. And as these changes occur, we will need to keep up. We should be looking ahead to the advancements that are likely to take place in the near future, and have some idea of how the law might react and accommodate such advances.

When we do this, will it dawn on us that as we progress our sequencing technology, human gene patents may provide an obstacle to advancements in the techniques used for whole genome or whole exome sequencing?

As this improvement occurs, can we be so sure that genetic sequencing will remain unaffected by the Myriad Genetics decision?

Is our current blasé attitude realistic, or short sighted?

© HopgoodGanim Lawyers

Award-winning law firm HopgoodGanim offers commercially-focused advice, coupled with reliable and responsive service, to clients throughout Australia and across international borders.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions